BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Shares Gap Up on Earnings Beat

BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT)’s stock price gapped up prior to trading on Friday after the company announced better than expected quarterly earnings. The stock had previously closed at $9.89, but opened at $10.45. BridgeBio Oncology Therapeutics shares last traded at $10.41, with a volume of 54,173 shares traded.

The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.67) by $0.18.

Trending Headlines about BridgeBio Oncology Therapeutics

Here are the key news stories impacting BridgeBio Oncology Therapeutics this week:

• Positive Sentiment: Publication of peer‑reviewed preclinical data for BBO‑11818 (panKRAS) in Cancer Discovery, highlighting potent activity against KRAS G12D/V/C, ON/OFF state inhibition, strong selectivity, and combination potential — adds scientific validation to BBOT’s lead KRAS program. Read More.
• Positive Sentiment: Early Phase 1 KONQUER‑101 clinical signals for BBO‑11818 (including a reported confirmed partial response in PDAC and encouraging anti‑tumor activity) support near‑term clinical upside and future data readouts expected H2 2026. Read More.
• Positive Sentiment: Quarterly results: BBOT reported EPS of ($0.49) vs. consensus ($0.67), beating estimates — a near‑term financial surprise that can reduce investor uncertainty around cash‑burn guidance and valuation assumptions. Read More.
• Positive Sentiment: HC Wainwright raised its price target to $29 and reiterated a Buy, signaling stronger sell‑side conviction and providing a high upside reference for investors. Read More.
• Neutral Sentiment: Corporate update/Q4 & FY‑2025 filing recap: BBOT summarized clinical progress across three RAS‑pathway programs (BBO‑8520, BBO‑11818, BBO‑10203) and reiterated combination strategies — useful context but largely already reflected in recent releases. Read More.
• Neutral Sentiment: Short‑interest data reported anomalies (0 shares / NaN change) for early March — appears to be a data glitch and unlikely to meaningfully explain price moves.
• Negative Sentiment: Key risk: important clinical and regulatory milestones (additional BBO‑11818 data and combination studies) are scheduled for H2 2026 — the multi‑quarter timeline sustains execution risk and valuation uncertainty until those readouts.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on BBOT shares. Raymond James Financial raised BridgeBio Oncology Therapeutics to a “moderate buy” rating in a research report on Friday, January 9th. HC Wainwright increased their price objective on shares of BridgeBio Oncology Therapeutics from $27.00 to $29.00 and gave the company a “buy” rating in a research report on Friday. Stifel Nicolaus assumed coverage on shares of BridgeBio Oncology Therapeutics in a research note on Tuesday, February 10th. They set a “buy” rating and a $23.00 price objective on the stock. Finally, Weiss Ratings began coverage on shares of BridgeBio Oncology Therapeutics in a research report on Wednesday, January 14th. They set a “sell (d+)” rating on the stock. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $26.00.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of BBOT. XTX Topco Ltd grew its position in shares of BridgeBio Oncology Therapeutics by 22.4% in the 4th quarter. XTX Topco Ltd now owns 28,633 shares of the company’s stock worth $358,000 after acquiring an additional 5,249 shares in the last quarter. Quadrature Capital Ltd acquired a new stake in shares of BridgeBio Oncology Therapeutics during the 4th quarter valued at approximately $162,000. Catalio Capital Management LP acquired a new stake in shares of BridgeBio Oncology Therapeutics during the 4th quarter valued at approximately $5,142,000. Armistice Capital LLC lifted its stake in BridgeBio Oncology Therapeutics by 142.7% during the fourth quarter. Armistice Capital LLC now owns 1,000,000 shares of the company’s stock worth $12,520,000 after purchasing an additional 588,000 shares during the last quarter. Finally, Paradigm Biocapital Advisors LP lifted its stake in BridgeBio Oncology Therapeutics by 21.2% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 2,261,749 shares of the company’s stock worth $28,317,000 after purchasing an additional 395,608 shares during the last quarter. Institutional investors own 54.89% of the company’s stock.

BridgeBio Oncology Therapeutics Trading Up 5.4%

The firm has a market capitalization of $833.50 million, a P/E ratio of -10.12 and a beta of 0.28.

About BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.